Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zonisamide - Eisai Co Ltd

Next Previous
Drug Profile

Zonisamide - Eisai Co Ltd

Alternative Names: AD-810; AD-810N; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Concordia Pharmaceuticals; Eisai Co Ltd; Sumitomo Pharma
  • Class Antidementias; Antiepileptic drugs; Antiparkinsonians; Benzoxazoles; Small molecules; Sulfonamides
  • Mechanism of Action Antioxidants; Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Parkinson's disease
  • Registered Lewy body disease
  • Discontinued Cerebral ischaemia; Manic episodes; Migraine; Neuropathic pain; Obesity

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 14 Jun 2021 ADVANZ PHARMA acquires rights to zonisamide from Eisai in the EU, Middle East, Russia and Australia
  • 18 Aug 2018 Dainippon Pharmaceutical completes a phase III trial in Parkinson's disease in Japan (UMIN000024859)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top